# Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis

> **NCT03615677** · PHASE3 · COMPLETED · sponsor: **Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.** · enrollment: 261 (actual)

## Conditions studied

- Erosive Esophagitis (EE)

## Interventions

- **DRUG:** LXI-15028 50mg
- **DRUG:** Esomeprazole 40mg

## Key facts

- **NCT ID:** NCT03615677
- **Lead sponsor:** Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-24
- **Primary completion:** 2019-10-18
- **Final completion:** 2019-10-18
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2020-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03615677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03615677, "Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT03615677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*